D
Avalo Therapeutics, Inc. AVTX
$13.99 $0.322.34% NASDAQ
Recommendation
Prev Close
$13.67
Volume
169,313
Avg Vol (90D)
264,135
Market Cap
$179.79M
Dividend & Yield
--
52-Week Range
$3.39 - $16.00
P/E (TTM)
--
EPS (TTM)
-$9.44
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Avalo Therapeutics' (AVTX) Sell (D-) Rating Reiterated at Weiss Ratings
10/14/2025 - MarketBeat
Avalo Therapeutics (AVTX, $13.95) RSI Indicator left the overbought zone on October 10, 2025
10/11/2025 - Tickeron - Stocks
Avalo Therapeutics (AVTX, $14.22) RSI Indicator left the overbought zone on October 08, 2025
10/9/2025 - Tickeron - Stocks
Avalo Therapeutics (AVTX, $13.48) RSI Indicator left the overbought zone on October 07, 2025
10/8/2025 - Tickeron - Stocks
Avalo Therapeutics (AVTX, $14) RSI Indicator left the overbought zone on October 06, 2025
10/7/2025 - Tickeron - Technical Analysis
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update
10/2/2025 - MarketBeat
Avalo Therapeutics Strengthens Leadership with Key Appointments
10/1/2025 - TipRanks Financial Blog
Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources
10/1/2025 - The Fly
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and ...
10/1/2025 - GuruFocus
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
10/1/2025 - Globe Newswire
Avalo Therapeutics' (AVTX) Buy Rating Reiterated at BTIG Research
9/30/2025 - MarketBeat
Avalo Therapeutics (AVTX, $13.02) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 29, 2025
9/30/2025 - Tickeron - Technical Analysis
Avalo Therapeutics (AVTX, $11.6) entered Uptrend as Momentum indicator ascends above 0 level on Sep 24, 2025
9/25/2025 - Tickeron - Technical Analysis
Avalo Therapeutics (AVTX, $11.25) entered Downtrend as Momentum indicator drops below 0 level on Sep 23, 2025
9/24/2025 - Tickeron - Stocks
Avalo Therapeutics (AVTX, $11.25) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 23, 2025
9/24/2025 - Tickeron - Stocks
Avalo Therapeutics Appoints Kevin Lind to Board
9/22/2025 - TipRanks Financial Blog
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
9/22/2025 - GuruFocus
Avalo Therapeutics appoints Kevin Lind to board of directors
9/22/2025 - The Fly
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
9/22/2025 - Globe Newswire
Avalo Therapeutics (AVTX, $11.79) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 19, 2025
9/20/2025 - Tickeron - Stocks
Avalo Therapeutics (NASDAQ:AVTX) Given New $25.00 Price Target at HC Wainwright
9/18/2025 - MarketBeat
Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright
9/17/2025 - The Fly
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update
9/16/2025 - MarketBeat
Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains
9/16/2025 - Simply Wall St
Avalo Therapeutics (AVTX) Gains Attention Ahead of Key Phase 2 Data Presentation
9/15/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$441.00K
EBITDA (TTM)
-$59.79M
EBIT (TTM)
-$60.16M
Net Income (TTM)
-$46.22M
Balance Sheet
Total Assets (Q)
$126.58M
Total Debt (Q)
$679.00K
Total Liabilities (Q)
$22.01M
Book Value Per Share (Q)
$9.65
Cash Flow
Cash from Operations (TTM)
-$47.42M
Cash from Investing (TTM)
-$70.86M
Cash from Financing (TTM)
$67.24M
Net Change in Cash (TTM)
-$51.04M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
0.96
7-Day Total Return
4.40%
30-Day Total Return
55.10%
60-Day Total Return
107.88%
90-Day Total Return
223.09%
Year to Date Total Return
65.95%
1-Year Total Return
50.59%
2-Year Total Return
-63.52%
3-Year Total Return
-98.90%
5-Year Total Return
-99.80%
52-week Low
May 14, 2025 - $3.39
52-week High
Oct 28, 2024 - $16.00
Valuation
Market Cap
$179.79M - Micro Cap
Enterprise Value
$67.21M
Price/Sales (TTM)
335.87
Price/Book (Q)
1.42
Dividends and Shares
Shares Outstanding
10.83
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.avalotx.com
Phone Number
410 522 8707
Address
540 Gaither Road
Rockville, MD 20850
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes... more
NASDAQ 10/14/2025 4:00PM Eastern Quotes delayed